After prostate surgery, men whose PSA levels drop to almost nothing (below 10 ng/L) are much less likely to have the cancer come back or die from it than those whose PSA stays higher.
Scientific Claim
In men with localized prostate cancer after radical prostatectomy, an ultrasensitive prostate-specific antigen (PSA) nadir below 10 ng/L is strongly associated with a significantly lower risk of biochemical recurrence and improved long-term survival, as demonstrated across 76 observational studies involving 67,479 patients.
Original Statement
“RP patients with the lowest post-surgery PSA nadir and patients who had the lowest PSA at SRT had the fewest deaths. ... PSAR-prone and non-PSAR-prone patients differed markedly in PSA nadir.”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The study design is a systematic review of observational cohort studies, which can only show association, not causation. The claim correctly uses 'associated with' and does not imply causation.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Systematic Review & Meta-AnalysisLevel 1aIn EvidenceThe strength and consistency of the association between PSA nadir <10 ng/L and survival across diverse populations and assay methods.
The strength and consistency of the association between PSA nadir <10 ng/L and survival across diverse populations and assay methods.
What This Would Prove
The strength and consistency of the association between PSA nadir <10 ng/L and survival across diverse populations and assay methods.
Ideal Study Design
A meta-analysis of individual patient data from 20+ prospective cohort studies (n≥50,000) of men undergoing radical prostatectomy for localized prostate cancer, all using standardized third-generation or higher ultrasensitive PSA assays, with minimum 10-year follow-up, measuring time to biochemical recurrence and overall survival as primary endpoints, adjusting for Gleason score, surgical margins, and age.
Limitation: Cannot prove that lowering PSA nadir itself causes improved survival, only that it correlates with it.
Randomized Controlled TrialLevel 1bWhether interventions that achieve a PSA nadir <10 ng/L (e.g., earlier SRT, intensified therapy) directly improve survival compared to standard care.
Whether interventions that achieve a PSA nadir <10 ng/L (e.g., earlier SRT, intensified therapy) directly improve survival compared to standard care.
What This Would Prove
Whether interventions that achieve a PSA nadir <10 ng/L (e.g., earlier SRT, intensified therapy) directly improve survival compared to standard care.
Ideal Study Design
A multicenter, double-blind RCT of 1,500 men with high-risk localized prostate cancer after radical prostatectomy, randomized to either immediate adjuvant radiotherapy (targeting PSA nadir <10 ng/L) vs. delayed salvage radiotherapy (triggered at PSA >200 ng/L), with primary endpoint of 10-year overall survival and secondary endpoints of metastasis-free survival and toxicity.
Limitation: Ethical and practical challenges in randomizing to potentially overtreat men with very low recurrence risk.
Prospective Cohort StudyLevel 2aIn EvidenceThe predictive accuracy of PSA nadir <10 ng/L for long-term outcomes in a real-world clinical setting.
The predictive accuracy of PSA nadir <10 ng/L for long-term outcomes in a real-world clinical setting.
What This Would Prove
The predictive accuracy of PSA nadir <10 ng/L for long-term outcomes in a real-world clinical setting.
Ideal Study Design
A prospective cohort study of 5,000 men undergoing radical prostatectomy, with serial ultrasensitive PSA measurements (third-gen or higher) every 3 months for 15 years, recording biochemical recurrence, metastasis, and death, with blinded adjudication and multivariable adjustment for clinical covariates.
Limitation: Cannot rule out unmeasured confounders (e.g., lifestyle, genetic factors) influencing both PSA nadir and survival.
Evidence from Studies
Supporting (1)
This study found that men with prostate cancer who have very, very low PSA levels after surgery are much less likely to have the cancer come back and are more likely to live longer — which matches what the claim says.